CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.21
+0.24%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$8.37
From 52W high−40.29%
Volume1.20M
Market cap$628.22M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$8.37
From 52W high
−40.29%
Volume
1.20M
Market cap
$628.22M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.7x
P/E (TTM)
—
RSI (14)
24.8
MomentumView details →
1D Return
+0.24%
YTD Return
+43.54%
SummaryUpdated Jun 1, 2026
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Needham, Massachusetts. Originally incorporated as Advantagene, Inc., the company rebranded to Candel Therapeutics in November 2020 before going public in July 2021. The company focuses on developing innovative immunotherapies designed to treat various forms of cancer by harnessing the body's immune system to fight tumors.
Similar companies
Latest newsMore news →
Candel Therapeutics presented new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk prostate cancer at the ASTRO Annual Meeting 2026.20d agoCandel Therapeutics shares rose 7.56% to $11.67 after an analyst upgraded the stock to Buy and raised the price target to $18 from $12.29d ago